(NASDAQ: KPTI) Karyopharm Therapeutics's forecast annual revenue growth rate of 17.24% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.15%.
Karyopharm Therapeutics's revenue in 2025 is $137,269,000.On average, 8 Wall Street analysts forecast KPTI's revenue for 2025 to be $1,320,722,352, with the lowest KPTI revenue forecast at $1,231,321,476, and the highest KPTI revenue forecast at $1,391,479,981. On average, 8 Wall Street analysts forecast KPTI's revenue for 2026 to be $1,442,206,957, with the lowest KPTI revenue forecast at $1,317,167,128, and the highest KPTI revenue forecast at $1,566,032,807.
In 2027, KPTI is forecast to generate $1,918,086,694 in revenue, with the lowest revenue forecast at $1,439,518,861 and the highest revenue forecast at $2,639,537,023.